# SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72

> **NIH NIH N01** · IRISYS, INC. · 2024 · $565,585

## Abstract

The scope of this contract is for formulation development of a solid oral dosage form as tablets, validation of analytical methods on drug products, manufacture of pilot batches, GMP drug product for a phase I clinical trial, and long term stability study under ICH guideline.

## Key facts

- **NIH application ID:** 11087443
- **Project number:** 271201700020I-P00001-759502300001-1
- **Recipient organization:** IRISYS, INC.
- **Principal Investigator:** ROBERT GIANNINI
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $565,585
- **Award type:** —
- **Project period:** 2023-09-29 → 2028-03-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11087443

## Citation

> US National Institutes of Health, RePORTER application 11087443, SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72 (271201700020I-P00001-759502300001-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11087443. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*